[1] |
ITO Y, TAKEDA R, TAKEDA Y. Subclinical primary aldosteronism[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26(4):485-495.
doi: 10.1016/j.beem.2011.11.006
pmid: 22863390
|
[2] |
宋颖, 何文雯, 冯正平, 等. 血压正常的原发性醛固酮增多症临诊应对[J]. 中华内分泌外科杂志, 2023, 17(3):376-377.
|
|
SONG Y, HE W W, FENG Z P, et al. Approach to a normotensive patient with primary aldosteronism[J]. Chin J Endoc Surg, 2023, 17(3):376-377.
|
[3] |
白求恩精神研究会内分泌和糖尿病学分会《2022年亚临床库欣综合征专家指导建议》编写组. 2022年亚临床库欣综合征专家指导建议[J]. 国际内分泌代谢杂志, 2023, 43(1):69-76.
|
|
Expert group for "Expert consensus on subclinical Cus-hing′s syndrome in China(2022)". Expert consensus on subclinical Cushing′s syndrome in China (2022)[J]. Int J Endocrinol Metab, 2023, 43(1):69-76.
|
[4] |
FAVERO V, CREMASCHI A, PARAZZOLI C, et al. Pathophysiology of mild hypercortisolism: from the bench to the bedside[J]. Int J Mol Sci, 2022, 23(2):673.
doi: 10.3390/ijms23020673
URL
|
[5] |
FAVERO V, CREMASCHI A, FALCHETTI A, et al. Management and medical therapy of mild hypercortisolism[J]. Int J Mol Sci, 2021, 22(21):11521.
doi: 10.3390/ijms222111521
URL
|
[6] |
CHIODINI I, ALBANI A, AMBROGIO A G, et al. Six controversial issues on subclinical Cushing's syndrome[J]. Endocrine, 2017, 56(2):262-266.
doi: 10.1007/s12020-016-1017-3
pmid: 27406391
|
[7] |
王冬, 王若秋, 朱兴艳, 等. 肾上腺醛固酮-皮质醇共分泌瘤2例报道并文献复习[J]. 国际内分泌代谢杂志, 2023, 43(5):418-421.
|
|
WANG D, WANG R Q, ZHU X Y, et al. Adrenal aldosterone and cortisol co-producing adenoma: Two cases report and literature review[J]. Int J Endocrinol Metab, 2023, 43(5):418-421.
|
[8] |
KITAJIMA N, SEKI T, YASUDA A, et al. A rare case of subclinical primary aldosteronism and subclinical Cus-hing's syndrome without cardiovascular complications[J]. Tokai J Exp Clin Med, 2016, 41(1):35-41.
|
[9] |
ICHIJO T, UESHIBA H, NAWATA H, et al. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features[J]. Endocr J, 2020, 67(2):141-152.
doi: 10.1507/endocrj.EJ18-0486
pmid: 31694993
|
[10] |
PAN L H, CHEN Y Y, PAN C T, et al. Follow-up care and assessment of comorbidities and complications in patients with primary aldosteronism: The clinical practice guideline of the Taiwan Society of aldosteronism[J/OL]. J Formos Med Assoc, 2023-08-22. https://linkinghub.elsevier.com/retrieve/pii/S0929-6646(23)00324-8.
|
[11] |
中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):727-736.
|
|
Chinese Society of Endocrinology. Expert consensus on the diagnosis and treatment of primary aldosteronism (2020)[J]. Chin J Endocrinol Metab, 2020, 36(9):727-736.
|
[12] |
中国内分泌代谢病专科联盟. 原发性醛固酮增多症诊治行业标准[J]. 中华内分泌代谢杂志, 2022, 38(7):555-557.
|
|
China Endocrinology and Metabolism Specialist Alliance. Standard for the diagnosis and treatment of primary aldosteronism[J]. Chin J Endocrinol Metab, 2022, 38(7):555-557.
|
[13] |
KMIEĆ P, SWORCZAK K. Autonomous aldosterone secretion as a subclinical form of primary aldosteronism: pathogenesis and clinical significance[J]. Exp Clin Endocrinol Diabetes. 2022 Jan; 130(1):7-16.
doi: 10.1055/a-1556-7784
URL
|
[14] |
FASSNACHT M, ARLT W, BANCOS I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the study of adrenal tumors[J]. Eur J Endocrinol, 2016, 175(2):G1-G34.
doi: 10.1530/EJE-16-0467
URL
|
[15] |
YANASE T, OKI Y, KATABAMI T, et al. New diagnostic criteria of adrenal subclinical Cushing's syndrome: opinion from the Japan Endocrine Society[J]. Endocr J, 2018, 65(4):383-393.
doi: 10.1507/endocrj.EJ17-0456
pmid: 29576599
|
[16] |
YOUNG W F. Primary aldosteronism: renaissance of a syndrome[J]. Clin Endocrinol (Oxf), 2007, 66(5):607-618.
doi: 10.1111/cen.2007.66.issue-5
URL
|
[17] |
STOWASSER M, GORDON R D. Primary aldosteronism-careful investigation is essential and rewarding[J]. Mol Cell Endocrinol, 2004, 217(1-2):33-39.
doi: 10.1016/j.mce.2003.10.006
URL
|
[18] |
MOSSO L, CARVAJAL C, GONZÁLEZ A, et al. Primary aldosteronism and hypertensive disease[J]. Hypertension, 2003, 42(2):161-165.
doi: 10.1161/01.HYP.0000079505.25750.11
pmid: 12796282
|
[19] |
BROWN J M, ROBINSON-COHEN C, LUQUE-FERNANDEZ M A, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study[J]. Ann Intern Med, 2017, 167(9):630-641.
doi: 10.7326/M17-0882
pmid: 29052707
|
[20] |
KMIEĆ P, ZALEWSKA E, KUNICKA K, et al. Autonomous aldosterone secretion in patients with adrenal incidentaloma[J]. Biomedicines, 2022, 10(12):3075.
doi: 10.3390/biomedicines10123075
URL
|
[21] |
李乐乐, 韩白玉, 窦京涛, 等. 午夜1 mg地塞米松抑制试验对肾上腺意外瘤中亚临床库欣综合征的诊断价值[J]. 中华医学杂志, 2015, 95(48):3912-3916.
|
|
LI L L, HAN B Y, DOU J T, et al. Evaluation of the 1 mg overnight dexamethasone suppression test in the diagnosis of the subclinical Cushing's syndrome in patients with adrenal incidentaloma[J]. Natl Med J China, 2015, 95(48):3912-3916.
|
[22] |
OJEDA N B, GRIGORE D, ROBERTSON E B, et al. Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring[J]. Hypertension, 2007, 50(4):679-685.
doi: 10.1161/HYPERTENSIONAHA.107.091785
pmid: 17724277
|